Hidonac Use In Pregnancy & Lactation

Pregnancy: There are limited clinical data from the use of acetylcysteine in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Prior to use in pregnancy, the potential risks should be balanced against the potential benefits.
Breast feeding: There is no information available on excretion in breast milk.
A risk to the suckling child cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from HIDONAC 5g/25ml therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility: No data is available on the effect of acetylcysteine on human fertility. Animal studies do not indicate harmful effects with respect to fertility for humans at the recommended doses (see Pharmacology: Toxicology: Preclinical safety data under Actions).